Morphological Cell Profiling of SARS-CoV-2 Infection Identifies Drug Repurposing Candidates for COVID-19
The global spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the associated disease COVID-19, requires therapeutic interventions that can be rapidly identified and translated to clinical care. Traditional drug discovery methods have a >90% failure rate and can take 10-15 years from target identification to clinical use. In contrast, drug repurposing can significantly accelerate translation. We developed a quantitative high-throughput screen to identify efficacious agents against SARS-CoV-2. From a library of 1,425 FDA-approved compounds and clinical candidates, we identified 17 dose-responsive compounds with in vitro antiviral efficacy in human liver Huh7 cells and confirmed antiviral efficacy in human colon carcinoma Caco-2, human prostate adenocarcinoma LNCaP, and in a physiologic relevant model of alveolar epithelial type 2 cells (iAEC2s). Additionally, we found that inhibitors of the Ras/Raf/MEK/ERK signaling pathway exacerbate SARS-CoV-2 infection in vitro. Notably, we discovered that lactoferrin, a glycoprotein classically found in secretory fluids, including mammalian milk, inhibits SARS-CoV-2 infection in the nanomolar range in all cell models with multiple modes of action, including blockage of virus attachment to cellular heparan sulfate and enhancement of interferon responses. Given its safety profile, lactoferrin is a readily translatable therapeutic option for the management of COVID-19.
| Errataetall: |
UpdateIn: Proc Natl Acad Sci U S A. 2021 Sep 7;118(36):. - PMID 34413211 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2020 |
|---|---|
| Enthalten in: |
bioRxiv : the preprint server for biology - (2020) vom: 07. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mirabelli, Carmen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 03.11.2022 published: Electronic UpdateIn: Proc Natl Acad Sci U S A. 2021 Sep 7;118(36):. - PMID 34413211 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2020.05.27.117184 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311561098 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311561098 | ||
| 003 | DE-627 | ||
| 005 | 20231225142521.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.05.27.117184 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1038.xml |
| 035 | |a (DE-627)NLM311561098 | ||
| 035 | |a (NLM)32577649 | ||
| 035 | |a (PII)2020.05.27.117184 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mirabelli, Carmen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Morphological Cell Profiling of SARS-CoV-2 Infection Identifies Drug Repurposing Candidates for COVID-19 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 03.11.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateIn: Proc Natl Acad Sci U S A. 2021 Sep 7;118(36):. - PMID 34413211 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a The global spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the associated disease COVID-19, requires therapeutic interventions that can be rapidly identified and translated to clinical care. Traditional drug discovery methods have a >90% failure rate and can take 10-15 years from target identification to clinical use. In contrast, drug repurposing can significantly accelerate translation. We developed a quantitative high-throughput screen to identify efficacious agents against SARS-CoV-2. From a library of 1,425 FDA-approved compounds and clinical candidates, we identified 17 dose-responsive compounds with in vitro antiviral efficacy in human liver Huh7 cells and confirmed antiviral efficacy in human colon carcinoma Caco-2, human prostate adenocarcinoma LNCaP, and in a physiologic relevant model of alveolar epithelial type 2 cells (iAEC2s). Additionally, we found that inhibitors of the Ras/Raf/MEK/ERK signaling pathway exacerbate SARS-CoV-2 infection in vitro. Notably, we discovered that lactoferrin, a glycoprotein classically found in secretory fluids, including mammalian milk, inhibits SARS-CoV-2 infection in the nanomolar range in all cell models with multiple modes of action, including blockage of virus attachment to cellular heparan sulfate and enhancement of interferon responses. Given its safety profile, lactoferrin is a readily translatable therapeutic option for the management of COVID-19 | ||
| 650 | 4 | |a Preprint | |
| 700 | 1 | |a Wotring, Jesse W |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Charles J |e verfasserin |4 aut | |
| 700 | 1 | |a McCarty, Sean M |e verfasserin |4 aut | |
| 700 | 1 | |a Fursmidt, Reid |e verfasserin |4 aut | |
| 700 | 1 | |a Frum, Tristan |e verfasserin |4 aut | |
| 700 | 1 | |a Kadambi, Namrata S |e verfasserin |4 aut | |
| 700 | 1 | |a Amin, Anya T |e verfasserin |4 aut | |
| 700 | 1 | |a O'Meara, Teresa R |e verfasserin |4 aut | |
| 700 | 1 | |a Pretto, Carla D |e verfasserin |4 aut | |
| 700 | 1 | |a Spence, Jason R |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Jessie |e verfasserin |4 aut | |
| 700 | 1 | |a Alysandratos, Konstantinos D |e verfasserin |4 aut | |
| 700 | 1 | |a Kotton, Darrell N |e verfasserin |4 aut | |
| 700 | 1 | |a Handelman, Samuel K |e verfasserin |4 aut | |
| 700 | 1 | |a Wobus, Christiane E |e verfasserin |4 aut | |
| 700 | 1 | |a Weatherwax, Kevin J |e verfasserin |4 aut | |
| 700 | 1 | |a Mashour, George A |e verfasserin |4 aut | |
| 700 | 1 | |a O'Meara, Matthew J |e verfasserin |4 aut | |
| 700 | 1 | |a Sexton, Jonathan Z |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv : the preprint server for biology |d 2020 |g (2020) vom: 07. Dez. |w (DE-627)NLM31090014X |7 nnns |
| 773 | 1 | 8 | |g year:2020 |g day:07 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.05.27.117184 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2020 |b 07 |c 12 | ||